IRF4 addiction in multiple myeloma.
Shaffer, Arthur L; Emre, N C Tolga; Lamy, Laurence; Ngo, Vu N; Wright, George; Xiao, Wenming; Powell, John; Dave, Sandeep; Yu, Xin; Zhao, Hong; Zeng, Yuxin; Chen, Bangzheng; Epstein, Joshua; Staudt, Louis M.
; 454(7201): 226-31, 2008 Jul 10.
Artigo em Inglês | MEDLINE | ID: mdl-18568025
Cancer: An unexpected addiction.
Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
Immunoregulatory roles of versican proteolysis in the myeloma microenvironment.
Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.
Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases.
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.
IRF4: Immunity. Malignancy! Therapy?
Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.
The role of long non-coding RNAs in multiple myeloma.